In 2009, Carl Ola Landgren noticed that nearly all of his multiple myeloma patients were responding to the state-of-the-art drugs he was giving them at the NCI clinical center in Building 10 in Bethesda.
In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models.
